Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05571839 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 20
- Study locations
NCT05571839 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Neoplasms that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 41 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05571839, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Neoplasms, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.
Conditions Studied
Interventions
- DRUG PF-08046049
Study Locations (20)
California
- UCLA Hematology/Oncology - Administrative Office - Los Angeles
- The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Ronald Reagan UCLA Medical Center, Drug Information Center - Los Angeles
- UCLA Hematology/Oncology - Los Angeles
- UCLA Hematology/ Oncology- Pasadena - Pasadena
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- UCSF Medical Center, Investigational Pharmacy - San Francisco
- UCLA Hematology/Oncology - Santa Barbara - Santa Barbara
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-up only) - Santa Monica
- UCLA Hematology - Oncology Clinic - Westlake Village - Westlake Village
Colorado
- Quest Diagnostics Incorporated - Denver - Denver
- Presbyterian/St. Lukes Medical Center - Denver
Illinois
- Northwestern Medical Group - Chicago
- Northwestern Memorial Hospital - Chicago
Massachusetts
- BWH - Boston
- Dana-Farber Cancer Institute (DFCI) - Boston
New York
- Ambulatory Care Center at NYU Langone Medical Center - New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
New Jersey
- Laboratory Corporation of America - Raritan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2026-06-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05571839
The ClinicalTrials.gov registry entry for NCT05571839 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which PF-08046049 is the first listed.
NCT05571839 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT05571839 about?
NCT05571839 is a clinical study titled "A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors". This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the...
What is the current status of trial NCT05571839?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-01-03. Estimated completion is 2026-06-06.
What conditions does trial NCT05571839 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Neoplasms, Mesothelioma, Pancreatic Neoplasms, Cutaneous Melanoma.
What interventions are being tested in trial NCT05571839?
The interventions under investigation include: PF-08046049 (DRUG).
Who is sponsoring clinical trial NCT05571839?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05571839 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.